The Medical Advisor

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...

Last updated: November 4, 2026 Emergency preparedness in the United States is entering a new era. Traditional disaster planning has focused on hurricanes, wildfires, floods, tornadoes, severe winter storms and power outages. But another threat increasingly deserves a place in every household emergency plan: cyberattacks against critical infrastructure. A sophisticated cyberattack does not necessarily need to shut down an entire power grid or telecommunications network to create serious consequences. Disrupting water-treatment controls, food refrigeration systems, healthcare networks, payment infrastructure or logistics operations can affect essential services that communities rely on every day. Recent incidents in the United States highlight this changing risk landscape. Federal authorities have warned about attacks affecting water and wastewater operations, while the Pentagon is investigating suspected cyber interference involving food refrigeration systems at military install...

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: November 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of November 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side e...